NutraIngredients | Oct 12, 2026

Cara Welch, director of FDA’s Office of Dietary Supplement Programs, said the agency is working to update supplement oversight and wants to collaborate with industry. Speakers at CHPA’s regulatory conference urged uniform rules, technology to flag misleading online claims, and a more predictable framework for new dietary ingredient notifications. The discussion signals how FDA could modernize the DSHEA framework without upending it.

NutraIngredients | Oct 7, 2026

FDA’s Office of Dietary Supplement Programs published a perspective on the manufacturing and testing challenges that make gummy supplements hard to dose accurately. The agency urged validated test methods and warned that ingredient overages should not mask poor production practices. NOW Foods called the guidance a valuable starting point but said stronger enforcement against bad actors is still needed.

The Healthy | Oct 8, 2026

Leader Formulas recalled a lot of RAPTURE Pre Workout after FDA testing detected DMAA, a stimulant the agency says is not a legal dietary ingredient. FDA classified the recall as Class I, its highest risk level. The case underscores FDA’s adulteration authority under DSHEA and the stakes of policing illegal stimulants in sports supplements.

HHS | Oct 9, 2026

HHS sent DEA a recommendation to control 7-OH and MGPI in Schedule I when concentrations exceed 1 mg per gram in solids or 1 mg per milliliter in liquids. DOJ said DEA issued new Notices of Intent incorporating those thresholds. The approach is designed to target concentrated opioid-like products while leaving natural botanical kratom outside the scheduling action.

Nutritional Outlook | Oct 6, 2026

The U.S. Supreme Court declined to hear the Council for Responsible Nutrition’s challenge to a New York law restricting sales of weight-loss and muscle-building supplements to people under 18. The case returns to district court, and CRN says the denial is not a ruling on the merits. Industry groups are watching closely as similar state measures, including California’s AB 2030, add to the patchwork that federal preemption proposals aim to address.

WholeFoods Magazine | Oct 8, 2026

A CRN survey of 3,005 U.S. adults found roughly three-quarters would have more confidence in supplements if manufacturers had to list products with FDA. CRN, which supports the Dietary Supplement Listing Act of 2026, said consumers also value stronger enforcement and independent quality verification. The poll adds fuel to the ongoing debate over whether mandatory listing belongs in DSHEA.

News-Medical | Oct 12, 2026

A year-long JAMA-published Norwegian trial of 410 people with early Parkinson’s found that nicotinamide riboside raised blood NAD levels but did not improve clinical outcomes. The result is a reminder for NAD+ precursor makers, including NMN brands, to keep structure/function claims within what the evidence supports. Regulators and critics often cite trials like this when scrutinizing disease-related messaging.

NutraIngredients | Oct 13, 2026

Australian brands have begun withdrawing andrographis products after the TGA barred the herb from new listed medicines over anaphylaxis concerns, with nine products recalled as of October 12. Companies are reformulating with alternatives such as mushroom and postbiotic blends. The episode shows how quickly a botanical can be pulled from the market under a stricter regime, a contrast U.S. advocates often draw with DSHEA’s burden-of-proof framework.

Your Voice Matters

FDA’s proposed rule on mandatory GRAS notification is open for public comment through December 9, 2026. Supplement stakeholders have until then to make their views on the proposal known to the agency.